L10.81 Paraneoplastic pemphigus

Name of the Condition

• Paraneoplastic pemphigus

Summary

Paraneoplastic pemphigus is a rare autoimmune blistering disorder associated with underlying malignancies. It causes painful blistering of the skin and mucous membranes, often with severe oral and respiratory involvement. The condition arises when the immune system produces antibodies against proteins in the skin and mucous membranes, leading to widespread blister formation and tissue damage.

Causes

Paraneoplastic pemphigus is caused by an autoimmune response triggered by an underlying cancer. The immune system produces antibodies that attack desmoglein and other proteins critical for cell adhesion in the skin and mucous membranes. This attack disrupts the connection between skin cells, resulting in blister formation. The exact mechanism linking the cancer to the autoimmune response is not fully understood, but the presence of a malignancy is a key factor.

Risk Factors

• Underlying malignancy: Most commonly associated with lymphomas, leukemias, or solid tumors.
• Age: Typically diagnosed in adults, often in those with a history of cancer.
• Cancer type: Higher risk with hematologic malignancies or certain solid tumors.
• Prior cancer treatment: Some cases may occur after chemotherapy or radiation therapy.

Symptoms

• Painful, widespread blisters on the skin and mucous membranes.
• Severe oral ulcers and erosions, often affecting the lips and mouth.
• Respiratory involvement, including bronchiolitis obliterans (airway obstruction).
• Skin lesions that may resemble Stevens-Johnson syndrome or toxic epidermal necrolysis.
• Mucosal involvement in the eyes, genitals, or gastrointestinal tract.

Diagnosis

Diagnosis involves a combination of clinical evaluation, biopsy, and laboratory testing. A skin or mucosal biopsy is examined for characteristic changes, such as suprabasal acantholysis and interface dermatitis. Direct and indirect immunofluorescence tests detect autoantibodies against epithelial cells. Blood tests may identify specific antibodies, and imaging or other studies confirm the underlying malignancy.

Treatment Options

Treatment focuses on managing the autoimmune response and addressing the underlying cancer. Immunosuppressive therapies, such as corticosteroids or rituximab, may control blistering. Plasmapheresis or intravenous immunoglobulin can reduce antibody levels. The underlying malignancy is treated with standard oncologic approaches, which may improve symptoms.

Prognosis and Follow-Up

Prognosis depends on the severity of the autoimmune response and the type of underlying cancer. Mortality is higher than in other pemphigus subtypes, often due to respiratory complications or the malignancy itself. Regular follow-up includes monitoring for cancer progression, managing treatment side effects, and assessing mucosal or respiratory involvement.

Complications

• Respiratory failure from bronchiolitis obliterans.
• Severe infections due to skin barrier disruption.
• Nutritional deficiencies from oral mucosal involvement.
• Treatment-related complications from immunosuppressive therapy.
• Progression of the underlying malignancy.

Lifestyle & Prevention

No specific prevention exists, as the condition is linked to cancer. Managing the underlying malignancy and adhering to treatment plans may reduce flare-ups. Avoiding triggers like certain medications or infections is recommended. Supportive care, such as wound care and pain management, improves quality of life.

When to Seek Professional Help

Seek immediate medical attention for:

• New or worsening blisters, especially in the mouth or throat.
• Difficulty breathing or respiratory symptoms.
• Signs of infection, such as fever or increased pain.
• Changes in cancer status or treatment response.

Tips for Medical Coders

Code L10.81 is specific to paraneoplastic pemphigus and requires documentation of the autoimmune blistering and its association with an underlying malignancy. Ensure clinical notes specify the condition and its link to cancer. Avoid coding for other pemphigus subtypes without clear differentiation. Document any relevant biopsies, antibody tests, or cancer diagnoses to support the code.